Loading
Myeloma expert who wrote the diagnostic criteria the field uses and a persistent critic of drug prices.
S. Vincent Rajkumar is Professor of Medicine in the Division of Hematology at Mayo Clinic and editor-in-chief of Blood Cancer Journal. A haematologist specialising in multiple myeloma and plasma cell disorders, he led the International Myeloma Working Group's updated diagnostic criteria, the criteria the field uses, and the randomised trials establishing lenalidomide-dexamethasone dosing. His papers include the Lancet Oncology report of the International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma and the Lancet Oncology open-label randomised trial of lenalidomide plus high-dose versus low-dose dexamethasone as initial therapy for newly diagnosed myeloma. He is also a persistent critic of drug prices, and his record links to BCMA.
Shares MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶), Mayo Clinic, Multiple myeloma.
Shares R-ISS / R2-ISS staging, MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶), BCMA, Multiple myeloma.
Shares BCMA, Multiple myeloma.
Shares BCMA, Multiple myeloma.
Shares BCMA, Multiple myeloma.
Shares BCMA, Multiple myeloma.
Shares BCMA, Multiple myeloma.
Shares BCMA, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/